Drugs in the Pipeline

The investigational product is an extended-release tablet formulation of diazoxide chloride, the crystalline salt of diazoxide.

The phase 3 STRIDE-10 trial evaluated the safety and immunogenicity of V116 in pneumococcal vaccine-naive adults 50 years of age and older.

The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for tapinarof cream, 1% for the topical treatment of atopic dermatitis (AD) in adults and children 2 years of age and older. Tapinarof is an aryl hydrocarbon receptor agonist currently marketed under the brand name Vtama® for the topical treatment of…

CTX-009 is a bispecific antibody that simultaneously blocks Delta-like ligand 4 and vascular endothelial growth factor A.

A phase 3, open-label study (MEND-PNPO) evaluating MC-1 in patients with confirmed PNPO deficiency (via genetic analysis) is currently in the works.

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for dostarlimab-gxly in combination with standard of care chemotherapy for all adult patients with primary advanced or recurrent endometrial cancer, including those with mismatch repair proficient (MMRp)/microsatellite stable (MSS) tumors. The sBLA is supported by data from part…

Prademagene zamikeracel is an autologous cell therapy that consists of epidermal sheets that deliver functional COL7A1 genes into the patient’s own skin cells to enable normal type VII collagen expression and facilitate wound healing.

Rilzabrutinib is an oral, reversible, covalent Bruton tyrosine kinase inhibitor.

AB-1002 is an investigational one-time gene therapy that promotes increased production of protein inhibitor 1.

The phase 3 SELECT-GCA study evaluated the efficacy and safety of upadacitinib in patients 50 years of age and older with GCA.